Corporate News Report: Haisco Pharmaceutical Group
Haisco Pharmaceutical Group Co., Ltd. (ticker 002653.SZ) closed its trading session on Wednesday, 21 September 2026, unchanged from the previous close, reflecting a flat 0 % movement over the 24‑hour period ending at 02:39 PM Central Europe. At the time of reporting, a single share was available for purchase at approximately CNY 60.30 on the Shenzhen Stock Exchange and other listed venues.
Market Snapshot
- Current share price: CNY 60.30
- Shares outstanding: 1.10 billion
- Market capitalization: CNY 63.40 billion
- Volume traded (last 24 h): CNY 233.8 million
- Price change since end‑of‑last‑month: –11.57 %
- 200‑day simple moving average: CNY 62.28
- 52‑week high: CNY 80.83 (06 July 2026)
- 52‑week low: CNY 42.38 (04 March 2026)
The flat closing price underscores a period of consolidation following a decline in the last month, yet the company’s valuation remains supported by its robust pipeline of hepatobiliary, anti‑infective, and nutritional products distributed across China.
Earnings Outlook and Strategic Progress
Sea‑Breeze Pharmaceuticals—commonly referenced by its ticker 002653—has announced a forward‑looking statement that anticipates a substantial increase in net profit for the first three quarters of 2026. This projection is underpinned by strong domestic sales of several flagship products, including anesthetic, metabolic, autoimmune, and oncology agents. In addition, the company has secured upfront payments from multiple new product‑licensing agreements, which are poised to inject significant cash flow once milestone conditions are satisfied.
Despite a rise in research and development expenditure, the firm highlights that profitability remains resilient, signalling a successful transition from an R&D‑heavy phase to a more commercially mature stage of its drug pipeline. Nonetheless, the company cautions that the total receipt of milestone payments is contingent upon meeting specific contractual thresholds, introducing an element of uncertainty into the projected cash inflow.
Peer Performance Overview
The following table summarizes the recent 24‑hour performance of selected peer stocks, offering context for Haisco’s market dynamics:
| Ticker | Current Price | % Change (24 h) | Market Cap | P/E Ratio |
|---|---|---|---|---|
| 1519.HK (J&T Global Express) | HKD 8.91 | –1.08 % | HKD 88.1 bn | 30.42 |
| 000988.SZ (Hgtech) | CNY 76.66 | 0 % | CNY 74.9 bn | 43.76 |
| 600039.SS (Sichuan Road & Bridge) | CNY 8.66 | 0 % | CNY 75.6 bn | 9.94 |
| 300015.SZ (Aier Eye Hospital) | CNY 7.97 | 0 % | CNY 73.8 bn | 28.98 |
| 1880.HK (China Tourism Duty F) | HKD 42.1 | –1.11 % | HKD 88.6 bn | 21.00 |
The relative stability of these peers—many of which are also experiencing flat trading days—suggests a broader market equilibrium, with isolated sectoral shifts rather than a systemic downturn.
Recent Strategic Acquisition by Aier Eye Hospital
Aier Eye Hospital, a prominent player in ophthalmic services, recently disclosed a strategic acquisition of a wholly‑owned medical service provider in Yunnan. The deal included a significant premium and a structured payment schedule, reinforced by protective clauses to safeguard the investment. By extending performance commitments through 2030, the acquisition aims to consolidate Aier’s eye‑care network in southwestern China, enhancing its end‑to‑end value chain from production to patient care.
This transaction aligns with an industry trend of consolidation, as firms seek to strengthen service networks amid slowing growth in high‑margin product lines. Management has emphasized that meeting performance targets is critical; failure to do so could trigger adjustments in valuation and potential goodwill impairment.
Company Profile
Haisco Pharmaceutical Group Co., Ltd. is headquartered in Shannan, China, and specializes in the development, manufacturing, and sale of drug formulations and active pharmaceutical ingredients. Its product portfolio focuses on hepatobiliary disease medications, anti‑infective drugs, and nutritional agents. The company markets its products nationwide and has been listed on the Shenzhen Stock Exchange since its IPO on 29 December 2011. For further information, visit the company’s website at www.haisco.com .
